|1.||Barriere, Steven L: 26 articles (10/2015 - 06/2005)|
|2.||Stryjewski, Martin E: 18 articles (10/2015 - 06/2005)|
|3.||Corey, G Ralph: 15 articles (10/2015 - 06/2005)|
|4.||Kitt, Michael M: 10 articles (01/2014 - 06/2005)|
|5.||Krause, Kevin M: 10 articles (12/2012 - 10/2005)|
|6.||Rubinstein, Ethan: 9 articles (03/2015 - 02/2008)|
|7.||Benton, Bret M: 9 articles (12/2012 - 08/2006)|
|8.||Hegde, Sharath S: 7 articles (12/2014 - 08/2004)|
|9.||Skinner, Robert: 6 articles (04/2010 - 08/2004)|
|10.||Van Bambeke, Françoise: 5 articles (12/2015 - 10/2004)|
01/01/2009 - "In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit. "
01/01/2015 - "Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus. "
12/01/2014 - "Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection."
06/01/2012 - "Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections."
07/01/2008 - "These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms."
12/01/2012 - "In phase 3 studies of the efficacy of telavancin for the treatment of hospital-acquired pneumonia, 704 Gram-positive and 627 Gram-negative aerobic bacterial pathogens were obtained at baseline from 1503 patients. "
10/01/2005 - "Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus."
12/01/2014 - "Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. "
04/01/2014 - "Clinigen Healthcare Ltd, Theravance's commercialization partner for telavancin in Europe, is in the process of seeking approval of a new manufacturing source.) A post hoc analysis of data from two Phase 3 ATTAIN trials of telavancin for the treatment of Gram-positive nosocomial pneumonia assessing clinical outcomes and safety. "
01/01/2014 - "The effect of applying these guidelines on outcomes of phase III nosocomial pneumonia studies of telavancin was evaluated in a post hoc analysis. "
07/01/2007 - "The results suggest that telavancin may be an effective treatment for endocarditis caused by glycopeptide-intermediate S. "
07/01/2007 - "The efficacy of telavancin, a novel lipoglycopeptide, was evaluated in experimental endocarditis in rabbits using two clinical isolates of glycopeptide-intermediate Staphylococcus aureus: ATCC 700788 and HIP 5836. "
07/01/2007 - "Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus."
06/01/2010 - "Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin."
06/01/2015 - "Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis."
06/01/2015 - "Further randomized, controlled trials are necessary to define the optimal role of telavancin in the treatment of MRSA bacteremia and IE."
01/01/2014 - "A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study."
06/01/2015 - "With limited effective agents in the treatment of MRSA-complicated bacteremia and IE, telavancin represents a potential treatment option. "
06/01/2015 - "This retrospective case series provides clinical evidence for the use of telavancin as a treatment option for refractory MRSA bacteremia and IE. "
06/01/2015 - "Of the 14 patients who received telavancin for refractory MRSA bacteremia and IE, eight survived their inpatient admission and were able to be followed for 30 days. "
|5.||Soft Tissue Infections
03/01/2009 - "Published phase II and III clinical trials have shown telavancin to be comparable to standard therapy for the treatment of complicated skin and soft tissue infections. "
11/15/2007 - "In trials evaluating telavancin for skin and soft-tissue infections, the dosage was 10 mg/kg i.v. once daily. "
11/15/2007 - "Telavancin was not inferior to standard treatment for complicated skin and soft-tissue infections in two Phase II clinical trials and two Phase III clinical trials. "
09/15/2015 - "Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment."
01/01/2011 - "Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections."
|1.||Mechanical Ventilators (Ventilator)
|5.||Length of Stay